PMID- 29319785
OWN - NLM
STAT- MEDLINE
DCOM- 20190308
LR  - 20220129
IS  - 2047-2412 (Electronic)
IS  - 2047-2404 (Linking)
VI  - 19
IP  - 7
DP  - 2018 Jul 1
TI  - Diagnostic accuracy and prognostic value of simultaneous hybrid 
      18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in 
      cardiac sarcoidosis.
PG  - 757-767
LID - 10.1093/ehjci/jex340 [doi]
AB  - AIMS: Cardiac death is the leading cause of mortality in patients with 
      sarcoidosis, yet cardiac involvement often remains undetected. Cardiovascular 
      magnetic resonance imaging (CMR) and 18F-fluorodeoxyglucose (FDG)-positron 
      emission tomography (PET) have been used to diagnose cardiac sarcoidosis (CS) yet 
      never simultaneously in a cohort. This study sought to assess the diagnostic and 
      prognostic utility of simultaneous hybrid cardiac PET/MR. METHODS AND RESULTS: 
      Fifty-one consecutive patients with suspected CS (age 50 +/- 13 years, 31 males) 
      underwent simultaneous PET/MR following a high-fat/low-carbohydrate diet and 12-h 
      fast. Blinded image analysis of FDG uptake and late gadolinium enhancement (LGE) 
      was performed using the American Heart Association (AHA) 16-segment model. The 
      sensitivity and specificity of PET/MR for diagnosing CS was estimated using the 
      Japanese Ministry of Health and Welfare guidelines. The primary endpoint was a 
      composite of death, aborted sudden cardiac death, sustained ventricular 
      arrhythmia, complete heart block, and hospital admission with decompensated heart 
      failure. The secondary endpoints were a fall in left ventricular ejection 
      fraction (LVEF) >10%, non-sustained ventricular tachycardia and other 
      cardiac-related hospital admission. The prevalence of CS was 65% (n = 33). The 
      sensitivity of PET and CMR alone for detecting CS was 0.85 and 0.82, 
      respectively. Hybrid PET/MR was superior for detecting CS with sensitivity, 
      specificity, positive, and negative predictive values of 0.94, 0.44, 0.76, and 
      0.80, respectively. There was poor inter-modality agreement for the location of 
      cardiac abnormalities (k = 0.02). Over the median follow-up of 2.2 years, there 
      were 18 (35%) adverse events. Cardiac RV PET abnormalities and presence of LGE 
      were independent predictors of adverse events. Abnormalities found on both PET 
      and magnetic resonance imaging was the strongest predictor of major adverse 
      cardiac events. CONCLUSION: Simultaneous PET/MR is an accurate method for 
      diagnosing CS. FDG-PET and CMR combined offers complementary information on 
      disease pathophysiology. The presence of LGE and FDG uptake on PET/MR identifies 
      patients at higher risk of adverse events. PET and CMR should therefore be 
      considered in the assessment of disease presence, stage, and prognosis in CS.
FAU - Wicks, Eleanor C
AU  - Wicks EC
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
AD  - Institute of Nuclear Medicine, University College London Hospitals, UK.
AD  - Oxford University Hospitals, John Radcliffe Hospital, Headley Way, Headington, 
      Oxford, OX3 9DU, UK.
FAU - Menezes, Leon J
AU  - Menezes LJ
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
AD  - Institute of Nuclear Medicine, University College London Hospitals, UK.
AD  - National Institute for Health Research University College London Hospitals and 
      Barts Heart Biomedical Research Centres, UK.
FAU - Barnes, Anna
AU  - Barnes A
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
AD  - Institute of Nuclear Medicine, University College London Hospitals, UK.
FAU - Mohiddin, Saidi A
AU  - Mohiddin SA
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
AD  - Institute of Nuclear Medicine, University College London Hospitals, UK.
FAU - Sekhri, Neha
AU  - Sekhri N
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
FAU - Porter, Joanna C
AU  - Porter JC
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
AD  - Department of Respiratory Medicine, University College London Hospitals, 5th 
      Floor, University College Hospital, 235 Euston Road, London, NW1 2BU, UK.
FAU - Booth, Helen L
AU  - Booth HL
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
AD  - Department of Respiratory Medicine, University College London Hospitals, 5th 
      Floor, University College Hospital, 235 Euston Road, London, NW1 2BU, UK.
FAU - Garrett, Emily
AU  - Garrett E
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
FAU - Patel, Riyaz S
AU  - Patel RS
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
AD  - National Institute for Health Research University College London Hospitals and 
      Barts Heart Biomedical Research Centres, UK.
FAU - Pavlou, Menelaos
AU  - Pavlou M
AD  - Department of Statistical Science, University College London, London, UK.
FAU - Groves, Ashley M
AU  - Groves AM
AD  - Institute of Nuclear Medicine, University College London Hospitals, UK.
AD  - National Institute for Health Research University College London Hospitals and 
      Barts Heart Biomedical Research Centres, UK.
FAU - Elliott, Perry M
AU  - Elliott PM
AD  - University College London Institute for Cardiovascular Science and Barts Heart 
      Centre, St. Bartholomew's Hospital, West Smithfield, EC1A 7BE, London, UK.
AD  - National Institute for Health Research University College London Hospitals and 
      Barts Heart Biomedical Research Centres, UK.
LA  - eng
GR  - FS/14/76/30933/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PL  - England
TA  - Eur Heart J Cardiovasc Imaging
JT  - European heart journal. Cardiovascular Imaging
JID - 101573788
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Cardiomyopathies/*diagnostic imaging/mortality/pathology
MH  - *Cause of Death
MH  - Cohort Studies
MH  - Death, Sudden, Cardiac
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - Image Processing, Computer-Assisted/methods
MH  - Magnetic Resonance Imaging, Cine/*methods
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging
MH  - Positron-Emission Tomography/*methods
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Sarcoidosis/*diagnostic imaging/mortality/pathology
MH  - Sensitivity and Specificity
MH  - Survival Analysis
MH  - Young Adult
EDAT- 2018/01/11 06:00
MHDA- 2019/03/09 06:00
CRDT- 2018/01/11 06:00
PHST- 2017/06/02 00:00 [received]
PHST- 2017/12/15 00:00 [accepted]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2019/03/09 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
AID - 4793104 [pii]
AID - 10.1093/ehjci/jex340 [doi]
PST - ppublish
SO  - Eur Heart J Cardiovasc Imaging. 2018 Jul 1;19(7):757-767. doi: 
      10.1093/ehjci/jex340.